Graham Dixon on Belinostat Plus CHOP in Patients With T-Cell Lymphoma

Graham Dixon, PhD
Published: Saturday, Feb 13, 2016



Graham Dixon, PhD, chief scientific officer, director of R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.

Belinostat is an HDAC inhibitor that was well tolerated in patients with peripheral T-cell lymphoma in the open-label, two-part study, Dixon explains, especially when combined with CHOP in the first-line setting. In this study, complete responses were reported in 67% of patients who received the combination. The overall response rate was 86%. 

Dixon hopes additional studies will reflect these findings and lead to an expanded approval of belinostat in the first-line setting. The agent is currently approved by the FDA as a second-line treatment of relapsed/refractory peripheral T-cell lymphoma. 


Graham Dixon, PhD, chief scientific officer, director of R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.

Belinostat is an HDAC inhibitor that was well tolerated in patients with peripheral T-cell lymphoma in the open-label, two-part study, Dixon explains, especially when combined with CHOP in the first-line setting. In this study, complete responses were reported in 67% of patients who received the combination. The overall response rate was 86%. 

Dixon hopes additional studies will reflect these findings and lead to an expanded approval of belinostat in the first-line setting. The agent is currently approved by the FDA as a second-line treatment of relapsed/refractory peripheral T-cell lymphoma. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
Publication Bottom Border
Border Publication
x